Five-year efficacy and safety of guselkumab for moderately to severely active Crohn’s disease: Results from the phase 2 GALAXI 1 trial
Inflammatory Bowel Diseases · 01.09.2026 · 32 (9) · 1669-1682
DOI: 10.1093/ibd/izag055 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 01.05.2026. Verfasst von Anita Afzali und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, University of Cincinnati College of Medicine, Cincinnati, OH, United States. Hauptthemen laut MEDLINE: Crohn Disease, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Johnson & Johnson.
Abstract (Originalsprache)
Background
The randomized, phase 2 GALAXI 1 study evaluated efficacy and safety of guselkumab, a dual-acting IL-23p19 subunit inhibitor, in participants with moderately to severely active Crohn’s disease. Efficacy and safety through 5 years are reported.
Methods
After completing the 48-week, treat-through GALAXI 1 main study, participants could enter the long-term extension (LTE) and continue the subcutaneous maintenance regimen assigned at randomization. Efficacy for the combined guselkumab dose groups was analyzed by (1) as-observed analysis of LTE participants, (2) nonresponder imputation (NRI) analysis of LTE participants, and (3) NRI analysis of primary efficacy analysis set (all [week 0] randomized participants). The study was not designed for statistical comparisons between groups.
Results
Of 185 guselkumab-randomized participants in the primary efficacy analysis set, 151 participated in the LTE. Among those continuing treatment, with available data (as observed), 97.7% (n = 85 of 87) achieved clinical remission, 71.3% (n = 62 of 87) achieved endoscopic response, and 51.7% (n = 45 of 87) achieved endoscopic remission at week 240. Results from NRI analyses also showed durability of efficacy (eg, week-240 clinical remission: 59.2% [n = 84 of 142], LTE analysis set; 46.0% [n = 81 of 176], primary efficacy analysis set). High rates of clinical and endoscopic remission at week 240 were maintained in biologic-naive participants (97.8% [n = 45 of 46] and 54.3% [n = 25 of 46], respectively [as-observed]) and participants with an inadequate response or intolerance to biologic therapy (97.1% [n = 34 of 35] and 54.3% [n = 19 of 35], respectively [as-observed]). Event rates of serious adverse events, discontinuations due to adverse events, and serious infections were low in guselkumab-treated participants.
Conclusions
Long-term guselkumab treatment showed sustained clinical and endoscopic efficacy through week 240. The long-term safety data were consistent with those previously presented in approved indications. Clinical trial registration A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn’s Disease (GALAXI), NCT03466411, https://clinicaltrials.gov/study/NCT03466411
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
- Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
- Inflammatory Bowel Disease Unit, University of Calgary, Calgary, AB, Canada.
- Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL, United States.
- Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
- Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria.
ORCID-Profile: Anita Afzali, Silvio Danese, Remo Panaccione, Bruce E Sands, Walter Reinisch, Wilbert van Duijnhoven, Tadakazu Hisamatsu
Förderung
- Johnson & Johnson
Zitieren
APA
Afzali, A., Danese, S., Panaccione, R., Rubin, D. T., Sands, B. E., Reinisch, W., Panés, J., Van Rampelbergh, R., Terry, N. A., Salese, L., Vetter, M. L., Yee, J., Corbett, C., van Duijnhoven, W., Hisamatsu, T., Andrews, J. M., D'Haens, G. R., & GALAXI 1 investigators (2026). Five-year efficacy and safety of guselkumab for moderately to severely active Crohn’s disease: Results from the phase 2 GALAXI 1 trial. Inflammatory Bowel Diseases, 32(9), 1669-1682. https://doi.org/10.1093/ibd/izag055
Vancouver
Afzali A, Danese S, Panaccione R, Rubin DT, Sands BE, Reinisch W, et al. Five-year efficacy and safety of guselkumab for moderately to severely active Crohn’s disease: Results from the phase 2 GALAXI 1 trial. Inflammatory Bowel Diseases. 2026;32(9):1669-1682. doi:10.1093/ibd/izag055
BibTeX
@article{Afzali2026,
author = {Afzali, Anita and Danese, Silvio and Panaccione, Remo and Rubin, David T and Sands, Bruce E and Reinisch, Walter and Panés, Julián and Van Rampelbergh, Rian and Terry, Nat A and Salese, Leonardo and Vetter, Marion L and Yee, Jacqueline and Corbett, Christopher and van Duijnhoven, Wilbert and Hisamatsu, Tadakazu and Andrews, Jane M and D'Haens, Geert R and GALAXI 1 investigators, GALAXI 1 investigators},
title = {Five-year efficacy and safety of guselkumab for moderately to severely active Crohn’s disease: Results from the phase 2 GALAXI 1 trial},
journal = {Inflammatory Bowel Diseases},
year = {2026},
volume = {32},
number = {9},
pages = {1669--1682},
doi = {10.1093/ibd/izag055}
}
EUVIMED